Jennifer Crombie, Md
Clinical trials sponsored by Jennifer Crombie, Md, explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New drug cocktail shows promise for Tough-to-Treat lymphoma Results expected Sep 2026 (estimated)
- New combo aims to boost CAR T-Cell therapy for rare lymphoma Results expected Jun 2027 (estimated)
-
New drug cocktail shows promise for Tough-to-Treat lymphoma
Disease control Recruiting nowThis study tests whether adding two newer drugs, glofitamab and polatuzumab, to standard chemotherapy (R-CHP) can improve outcomes for people with high-risk diffuse large B-cell lymphoma. About 41 adults with untreated CD20-positive lymphoma will receive the combination. The main…
Phase 2 • Sponsor: Jennifer Crombie, MD • Aim: Disease control
Last updated Jun 27, 2026 09:11 UTC
-
New combo aims to boost CAR T-Cell therapy for rare lymphoma
Disease control Recruiting nowThis phase 2 trial tests whether adding the immunotherapy drug pembrolizumab (Keytruda) to standard CAR T-cell therapy can improve outcomes for people with relapsed or refractory primary mediastinal B-cell lymphoma. About 35 participants will receive pembrolizumab before and afte…
Phase 2 • Sponsor: Jennifer Crombie, MD • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC